Rifaximin Versus Lactulose in Renal Failure

Phase 4

Withdrawn

• Conditions: Renal Failure; Liver Cirrhosis
• Interventions: Drug: Rifaximin; Drug: Lactulose

• Registration Number: NCT00748904
• Lead Sponsor: Weill Medical College of Cornell University

Brief Summary

The purpose of this study is to evaluate patients with cirrhosis of the liver and renal failure and determine if the administration of rifaximin as compared to lactulose is associated with less frequent and/or slower progression to severe hepatic encephalopathy. If one is associated with lower blood ammonia levels. And, if one is associated with lower breath hydrogen and methane levels.

Detailed Description

Not available

Study Timeline

• Study Start: 2008-06
• Study First Submitted: 2008-09-08
• Study First Submitted QC: 2008-09-08
• Study First Posted: 2008-09-09
• Primary Completion: 2009-07
• Study Completion: 2009-07
• Status Verified: 2022-01
• Last Update Submitted: 2022-01-24
• Last Update Posted: 2022-02-08

Recruitment & Eligibility

• Status: WITHDRAWN
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

• cirrhosis of liver of any etiology
• progressive renal failure
• stage 0-2 hepatic encephalopathy

Exclusion Criteria

• pregnant women

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
A	Rifaximin	35 patients receiving rifaximin
B	Lactulose	35 patients receiving lactulose

Primary Outcome Measures

Name	Time	Method
slower progression to severe hepatic encephalopathy, stage 3 or 4	during hospitalization

Trial Locations

Locations (1)

Weill Cornell Medical Center; 🇺🇸 New York, New York, United States